TW-37

Catalog No.S1121

For research use only.

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

TW-37 Chemical Structure

CAS No. 877877-35-5

Selleck's TW-37 has been cited by 44 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Other Bcl-2 Products

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell NFH1T2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHsTY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[gcm0> MWrTRW5ITVJ?
human Ca9-22 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnXUIpKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJibl2= NYDPVoI2W0GQR1XS
human CHL-1 cell MkfvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3Tn[GlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU46KG6P MlfEV2FPT0WU
human A549 cell MoTBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\KVY5FUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvODlibl2= MXTTRW5ITVJ?
human RKO cell NX7uUZQ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIDDOIJKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlE4KG6P NUXwOW42W0GQR1XS
human GCIY cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvHUHZKdmirYnn0bY9vKG:oIHj1cYFvKEeFSWmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE45OyCwTR?= MnjYV2FPT0WU
human BHT-101 cell NF[5TIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU45OyCwTR?= NHjKWYNUSU6JRWK=
human Hs-578-T cell NVT2OmtST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fmTmlvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOy53OTDuUS=> NI\hXYhUSU6JRWK=
human SK-UT-1 cell NXzKfYhpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLSVmR5UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjhwNkigcm0> MnzXV2FPT0WU
human NB7 cell NGf0[VFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVn1OnhKUW6qaXLpeIlwdiCxZjDoeY1idiCQQkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU4zQCCwTR?= MnezV2FPT0WU
human YKG-1 cell M4XnZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nTO2lvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU44PiCwTR?= M2\GfnNCVkeHUh?=
human HuH-7 cell M1zK[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXubYRpUW6qaXLpeIlwdiCxZjDoeY1idiCKdVitO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMzNjh{IH7N M37VUHNCVkeHUh?=
human SAS cell NEnmXo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHPzd5ZKdmirYnn0bY9vKG:oIHj1cYFvKFODUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOzMlE5KG6P MYTTRW5ITVJ?
human UACC-62 cell NUHsdYJMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4{PSCwTR?= MmCzV2FPT0WU
human AGS cell NG\qU4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGmzdG1KdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlU{KG6P NEjQbZNUSU6JRWK=
human SK-MEL-30 cell M1yzfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7pT5lKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN5Lkm3JI5O NInQVGpUSU6JRWK=
human A427 cell Mn[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlvoTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NESuOlkhdk1? MX3TRW5ITVJ?
human DU-145 cell M1noTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MljJTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk4yOyCwTR?= NUC0VHc4W0GQR1XS
human HCT-116 cell MlfDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkLTTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVIvPjZibl2= NYfTbGZ2W0GQR1XS
human A673 cell MknhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHKTY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOuPFUhdk1? M1e0[nNCVkeHUh?=
human SF126 cell NHy2XplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHqyd2xKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVcvODdibl2= MkG5V2FPT0WU
human SW872 cell M{PZTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUiuPUBvVQ>? MlGxV2FPT0WU
human NCI-H1581 cell M4fSemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWr6VG0xUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2QDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Nz62OEBvVQ>? MUDTRW5ITVJ?
human SK-MEL-5 cell NUXDZlVST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1GxdWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS5{NTDuUS=> MXjTRW5ITVJ?
human CP50-MEL-B cell M1PWPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnSxTY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwNUmgcm0> MkfUV2FPT0WU
human YH-13 cell NGDwdnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV73WIE2UW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcxNjV7IH7N NFHpO|lUSU6JRWK=
human LXF-289 cell M3HSSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPGd5lKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04Oi56NTDuUS=> Mn;LV2FPT0WU
human MC-IXC cell MnnZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4TJVGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|UvOzNibl2= MVHTRW5ITVJ?
human NB14 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWfFVWxyUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|YvPDVibl2= NIjqfnVUSU6JRWK=
human HEC-1 cell MoqzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoGzTY5pcWKrdHnvckBw\iCqdX3hckBJTUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUixMlM4KG6P MmPOV2FPT0WU
human U-87-MG cell MkHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHUuQDdvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Nk4zPCCwTR?= M3rtN3NCVkeHUh?=
human HOS cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWTQOYpFUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24OE44OSCwTR?= NETIS|RUSU6JRWK=
human HUTU-80 cell M{CxZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFTYSZJKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Py5yMTDuUS=> NYTDdZBmW0GQR1XS
human A375 cell NX3yWZdnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGm0SYpKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24PE45OyCwTR?= MmTNV2FPT0WU
human A204 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvWW2JKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25O{45PCCwTR?= M1;2VHNCVkeHUh?=
human GB-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfIbZlbUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVgvPjlibl2= MYnTRW5ITVJ?
human MDA-MB-231 cell NFO2V3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyOEC3JO69VQ>? MnrsV2FPT0WU
human SW982 cell NIDQb|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVy4R2NtUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFyNzFOwG0> NHH6[G1USU6JRWK=
human SW756 cell M3fOSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX;DVZFwUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{M{[g{txO NHXnRlNUSU6JRWK=
human MG-63 cell M{G3O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVI1QCEQvF2= M1izTnNCVkeHUh?=
human Daoy cell NF\DOHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjmW29JUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPDB5MzFOwG0> M3TTbnNCVkeHUh?=
human MDA-MB-453 cell MoXIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIPWdm1KdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NVg5KM7:TR?= M4qwOnNCVkeHUh?=
human HT-144 cell NFzG[VlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\DVGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTJyMTFOwG0> MWjTRW5ITVJ?
human LoVo cell MlyyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUTJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFk{KM7:TR?= NEnOTpRUSU6JRWK=
human NY cell NIjKZ|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3r4dGlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3O|YzKM7:TR?= MVjTRW5ITVJ?
human SW1783 cell NXS3cZNnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWPCcXplUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3PFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJzM{CxJO69VQ>? MWLTRW5ITVJ?
human A2780 cell NFvJUldIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYrJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVg1PiEQvF2= MoXpV2FPT0WU
human MDA-MB-361 cell NEXKS4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYO2V3lwUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlY1KM7:TR?= Mn7lV2FPT0WU
human RPMI-2650 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvMk[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN6M{Gg{txO NVTKNWpQW0GQR1XS
In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

    For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].

Cell Research:[2]
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
Animal Research:[3]
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.

Solubility (25°C)

In vitro

DMSO 115 mg/mL
(200.45 mM)
Ethanol 4 mg/mL
(6.97 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor